NICE, in collaboration with other international health technology assessment agencies, has published a new report which ...
Marstacimab for treating severe haemophilia A or severe haemophilia B in people 12 years and over [ID6342] Draft guidance Technology appraisal guidance 6 February 2025 Capivasertib with fulvestrant ...
This guideline covers nutrition and weight management in pregnancy for anyone who may become pregnant, is planning to become pregnant or is already pregnant, and nutrition in children up to 5 years.
This guideline covers the prevention and management of overweight, obesity and central adiposity in children, young people and adults. It brings together and updates all NICE's previous guidelines on ...
The 4 technology appraisal committees are standing advisory committees of NICE. This topic was considered by committee C. Committee members are asked to declare any interests in the technology being ...
There is a simple discount patient access scheme for vamorolone. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...
There is a simple discount patient access scheme for durvalumab. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...
NICE has developed tools and resources, in association with relevant stakeholders, to help organisations put this guidance into practice. The evidence generation plan gives further information on the ...
People have the right to be involved in discussions and make informed decisions about their care, as described in NICE's information on making decisions about your care. Making decisions using NICE ...
Vamorolone (Agamree) is available on the NHS as a possible treatment for Duchenne muscular dystrophy (DMD) in people 4 years and over. Is this treatment right for me? Your healthcare professionals ...
Durvalumab (Imfinzi, AstraZeneca) with platinum-based chemotherapy as neoadjuvant treatment, and then as monotherapy after surgery, is indicated for 'the treatment of adults with resectable (tumours ≥ ...